TheraBiome’s patented GEMICEL® oral delivery platform is phase 2 ready and enables our partners to precisely target drugs and biologics to the colon, or to both the small intestine and colon, for local or systemic therapy.  This colon- or dual-targeted technology enhances therapeutic efficacy while minimizing side effects of small molecules, peptides, proteins, live biotherapeutic products (LBP), and vaccines through controlled-release formulations. GEMICEL overcomes limitation of the conventional enteric coatings, facilitates the developability of new or revamping of failed drugs, is differentiated and provides access to an extended product life cycle management. Human scintigraphy confirms reliable payload delivery to specific sites within the GI tract through pH- and pressure-dependent release mechanisms.

Led by experienced team, Therabiome builds on the Assembly Bio/ Allergan collaboration which advanced GEMICEL technology to the clinic for treating inflammatory bowel disease (IBD), e.g.,  ulcerative colitis and Crohn’s disease. TheraBiome is keenly seeking partners who may benefit from leveraging GEMICEL’s precision GI-targeting capabilities and invites collaborations for licensing, co-development, and acquisition to advance drug innovation across diverse therapeutic areas.